All Publications

  • 3D-Printed Microarray Patches for Transdermal Applications JACS AU Rajesh, N. U., Coates, I., Driskill, M. M., Dulay, M. T., Hsiao, K., Ilyin, D., Jacobson, G. B., Kwak, J., Lawrence, M., Perry, J., Shea, C. O., Tian, S., DeSimone, J. M. 2022
  • Oral mRNA delivery using capsule-mediated gastrointestinal tissue injections MATTER Abramson, A., Kirtane, A. R., Shi, Y., Zhong, G., Collins, J. E., Tamang, S., Ishida, K., Hayward, A., Wainer, J., Rajesh, N., Lu, X., Gao, Y., Karandikar, P., Tang, C., Lopes, A., Wahane, A., Reker, D., Frederiksen, M., Jensen, B., Langer, R., Traverso, G. 2022; 5 (3): 975-987
  • The entry of nanoparticles into solid tumours NATURE MATERIALS Sindhwani, S., Syed, A., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N., Hoang, T., Wu, J. Y., Wilhelm, S., Zilman, A., Gadde, S., Sulaiman, A., Ouyang, B., Lin, Z., Wang, L., Egeblad, M., Chan, W. W. 2020; 19 (5): 566-+


    The concept of nanoparticle transport through gaps between endothelial cells (inter-endothelial gaps) in the tumour blood vessel is a central paradigm in cancer nanomedicine. The size of these gaps was found to be up to 2,000 nm. This justified the development of nanoparticles to treat solid tumours as their size is small enough to extravasate and access the tumour microenvironment. Here we show that these inter-endothelial gaps are not responsible for the transport of nanoparticles into solid tumours. Instead, we found that up to 97% of nanoparticles enter tumours using an active process through endothelial cells. This result is derived from analysis of four different mouse models, three different types of human tumours, mathematical simulation and modelling, and two different types of imaging techniques. These results challenge our current rationale for developing cancer nanomedicine and suggest that understanding these active pathways will unlock strategies to enhance tumour accumulation.

    View details for DOI 10.1038/s41563-019-0566-2

    View details for Web of Science ID 000508172300001

    View details for PubMedID 31932672

  • Theoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson's Disease. The Yale journal of biology and medicine Qudrat, A., Unni, N. 2016; 89 (2): 215-25


    Parkinson's disease is a late-onset neurodegenerative disease, characterized by both motor and non-motor symptoms. Motor symptoms include postural instability, rigidity, and tremor, while non-motor symptoms include anxiety, dementia, and depression. In this integrative review, we discuss PD disease pathophysiology in detail and introduce how neurotrophic growth factor delivery via a retroviral-based system can be used as efficacious tools for targeted gene therapy.

    View details for PubMedID 27354847

    View details for PubMedCentralID PMC4918865